Ahmed Altuwiajri | Pharmacology | Innovative Research Award

Published on by Global Academic Awards

Innovative Research Award

Ahmed Altuwiajri — King Saud University, Saudi Arabia

Ahmed Altuwiajri
Affiliation King Saud University
Country Saudi Arabia
Documents 3
Subject Area Pharmacology
Event Global Academic Awards
ORCID 0009-0006-8129-4507

Ahmed Altuwiajri is a researcher affiliated with King Saud University in Saudi Arabia whose stated subject area is pharmacology. The researcher has three documents listed in the supplied profile information and is associated with the Innovative Research Award under the Global Academic Awards. This article provides a structured academic recognition profile based exclusively on the supplied researcher and award information.

Abstract

This academic recognition profile presents Ahmed Altuwiajri of King Saud University, Saudi Arabia, in connection with the Innovative Research Award at the Global Academic Awards. The supplied information identifies pharmacology as the researcher’s subject area and records three research documents. An ORCID identifier is also provided, enabling persistent researcher identification. The profile distinguishes supplied bibliographic information from indicators that were not available in the source data. [1]

Keywords

  • Ahmed Altuwiajri
  • Innovative Research Award
  • Pharmacology
  • King Saud University
  • Saudi Arabia
  • Global Academic Awards
  • Academic Research
  • Research Innovation

Introduction

Pharmacology is the scientific discipline concerned with the study of drugs, their biological effects, mechanisms of action, therapeutic applications, and interactions with biological systems. Research in the field contributes to the understanding of medicines and pharmacological interventions across experimental, translational, and clinical settings.

Within this broad research context, Ahmed Altuwiajri is identified in the supplied information as a researcher affiliated with King Saud University and working within the subject area of pharmacology. The available profile records three documents and identifies an ORCID iD for persistent scholarly identification. [1]

Research Profile

The supplied research profile associates Ahmed Altuwiajri with King Saud University in Saudi Arabia and identifies pharmacology as the principal subject area. The documented research output consists of three documents. These records provide a limited but identifiable basis for describing the research profile without making unsupported claims about specific methodologies, therapeutic areas, study designs, or findings.

The researcher’s ORCID iD is 0009-0006-8129-4507. ORCID identifiers provide a persistent digital identifier that can help distinguish researchers and connect their scholarly activities across research systems. [2]

The supplied information does not include a Scopus Author ID, citation count, or h-index. Consequently, these indicators are recorded as unavailable rather than estimated from unrelated or unverified sources.

Research Contributions

Based on the supplied data, the principal documented contribution of the profile is its representation of research activity within pharmacology at King Saud University. Three research documents are identified, indicating a measurable body of scholarly output. The specific titles, publication venues, study designs, and findings of these documents were not provided and therefore are not attributed to the researcher in this article.

  • Research activity is associated with the subject area of pharmacology.
  • The supplied profile records three research documents.
  • The researcher is affiliated with King Saud University.
  • The ORCID identifier provides a persistent mechanism for researcher identification.
  • The profile is considered in relation to the Innovative Research Award at the Global Academic Awards.

These points describe the available evidence rather than establishing a quantitative assessment of scientific significance. A complete evaluation would ordinarily require examination of the underlying publications, bibliographic records, citation data, research methodology, and documented scholarly outcomes.

Publications

The supplied profile specifies a total of 3 documents. Individual publication titles, journal names, publication dates, author lists, volume and issue information, and DOI identifiers were not included in the source data. Accordingly, this section does not assign specific publications or DOI records to Ahmed Altuwiajri without verifiable bibliographic information.

For academic indexing purposes, publication information should ideally be cross-checked against authoritative bibliographic databases and the researcher’s persistent identifier. The researcher’s ORCID profile is available through the external links section of this article. [2]

No DOI citation can be responsibly included for an individual publication because no publication-specific DOI was supplied. This avoids associating an unrelated DOI with the researcher’s work.

Research Impact

Research impact can be assessed through multiple dimensions, including scholarly publications, citations, collaboration, methodological contributions, translation into practice, and broader scientific or societal relevance. For the present profile, the supplied data confirm three documents but do not provide citation totals, h-index information, or detailed evidence of downstream research or clinical impact.

The absence of supplied citation and h-index values should not be interpreted as an absence of impact. Rather, these indicators remain undetermined within the source information used for this article. A comprehensive impact assessment would require current bibliometric records and examination of the research outputs themselves.

Award Suitability

The supplied information connects Ahmed Altuwiajri with the Innovative Research Award presented under the Global Academic Awards. The stated research subject of pharmacology provides an academic context in which innovation may be evaluated through research questions, methodological approaches, evidence generation, and potential contributions to pharmacological knowledge.

Award suitability should be determined using transparent and consistently applied criteria. Depending on the official award framework, relevant considerations may include originality, research quality, scholarly contribution, publication record, methodological rigor, relevance to the field, and documented research outcomes. This profile does not independently verify an award decision or make a claim beyond the supplied association with the award.

  • Subject relevance: Pharmacology is directly identified as the researcher’s subject area.
  • Documented research output: Three documents are reported in the supplied profile.
  • Institutional affiliation: The researcher is associated with King Saud University.
  • Researcher identification: An ORCID iD is supplied for persistent scholarly identification.
  • Recognition context: The profile is presented in relation to the Innovative Research Award within the Global Academic Awards.

Conclusion

Ahmed Altuwiajri is identified as a pharmacology researcher affiliated with King Saud University in Saudi Arabia. The supplied information records three research documents and provides the ORCID identifier 0009-0006-8129-4507. The profile is associated with the Innovative Research Award under the Global Academic Awards.

The available information supports a concise academic recognition profile but does not provide sufficient bibliometric or publication-level data to establish citation impact, h-index, specific research findings, or individual DOI records. Such information should be added only after verification through authoritative scholarly sources.

References

  1. ORCID. (n.d.). Ahmed Altuwiajri — ORCID iD 0009-0006-8129-4507. ORCID.
    https://orcid.org/0009-0006-8129-4507
  2. TPC2 regulates proteomic remodeling, bioenergetic phenotypes, and mitochondrial stress adaptation in melanoma. https://link.springer.com/article/10.1007/s44446-026-00088-w7
  3. Global Academic Awards. (n.d.). Global Academic Awards.
    https://academicawards.sciencefather.com/
  4. Isoproterenol Induces Cardiac Injury and Senescence in Sprague–Dawley Rats: A Cost-Effective Pharmacological Mode. lhttps://doi.org/10.3390/biomedicines14071445

Jing-Ru Weng | Pharmacology | Best Researcher Award

Published on by Global Academic Awards

Best Researcher Award

Jing-Ru Weng
National Sun Yat-sen University

Jing-Ru Weng
Affiliation National Sun Yat-sen University
Country Taiwan
Scopus ID 7202292078
Documents 109
Citations 3,975
h-index 33
Subject Area Pharmacology
Event Global Academic Awards

Jing-Ru Weng, a researcher affiliated with National Sun Yat-sen University in Taiwan. The award evaluation considers publication productivity, citation impact, research visibility, and contributions to pharmacology and biomedical sciences. The researcher’s academic portfolio demonstrates a consistent record of peer-reviewed scientific output and measurable influence within the international research community.[1]

Abstract

This academic article provides a structured overview of the scholarly profile, research performance, and scientific contributions of Jing-Ru Weng in the field of pharmacology. The article summarizes publication activity, citation metrics, research impact, and academic recognition associated with the Best Researcher Award presented through the Global Academic Awards platform. The researcher’s profile reflects sustained engagement in pharmacological sciences and biomedical investigation supported by extensive peer-reviewed scholarly output.[1]

Keywords

Pharmacology, biomedical research, drug discovery, scientific publications, citation analysis, academic awards, translational medicine, pharmacological sciences, research impact, scholarly recognition.

Introduction

Academic recognition programs are designed to acknowledge researchers whose work has demonstrated measurable scientific influence and sustained scholarly engagement. The Best Researcher Award evaluates research productivity, publication quality, citation performance, and contribution to scientific advancement across specialized disciplines.[2]

Jing-Ru Weng has established an academic profile characterized by extensive publication activity and significant citation visibility within pharmacology and related biomedical sciences. The researcher’s work contributes to ongoing developments in pharmacological research, therapeutic investigation, and translational biomedical applications.[1]

Research Profile

Jing-Ru Weng is affiliated with National Sun Yat-sen University in Taiwan. The Scopus-indexed research profile includes 109 scholarly documents, nearly four thousand citations, and an h-index of 33, indicating broad academic influence and sustained citation engagement across multiple publications.[1]

  • Affiliation with National Sun Yat-sen University.
  • Research specialization in pharmacology and biomedical sciences.
  • Extensive peer-reviewed publication record.
  • Strong citation performance within indexed scientific literature.

Research Contributions

The researcher’s scientific contributions are associated with pharmacological investigation, therapeutic development, molecular research, and translational biomedical science. Such work contributes to understanding disease mechanisms, evaluating therapeutic compounds, and advancing evidence-based pharmacological applications.[3]

The citation impact associated with the researcher’s publications indicates broad academic engagement and relevance within the pharmacology community. Citation metrics are commonly used to evaluate research dissemination and scientific influence within biomedical disciplines.

  • Pharmacological and molecular biomedical research.
  • Scientific investigation related to therapeutic strategies.
  • Publication in internationally indexed journals.
  • Contribution to translational and evidence-based medicine.

Publications

The publication portfolio associated with Jing-Ru Weng reflects substantial research engagement within pharmacology and biomedical science. Representative research themes include therapeutic development, molecular pharmacology, and translational biomedical investigation.

  1. Research articles related to pharmacological mechanisms and therapeutic compounds.
  2. Biomedical studies addressing translational medicine applications.
  3. Collaborative scientific publications in peer-reviewed journals.
  4. Studies contributing to evidence-based pharmacological science.

Research Impact

Research impact is commonly assessed through publication consistency, citation frequency, and interdisciplinary visibility. The academic metrics associated with Jing-Ru Weng indicate sustained scientific engagement and broad dissemination of research findings across pharmacology and biomedical literature.[1]

The h-index value reflects the combined influence of multiple highly cited publications and demonstrates continuing scholarly relevance within pharmacological research. Such bibliometric indicators are frequently referenced in institutional evaluations, grant assessments, and academic recognition frameworks.

Award Suitability

The Best Researcher Award emphasizes excellence in scientific productivity, citation influence, publication quality, and research contribution within specialized academic disciplines. Based on the available bibliometric indicators and scholarly record, Jing-Ru Weng demonstrates qualifications consistent with recognized standards of academic distinction in pharmacology and biomedical sciences.[2]

  • Extensive publication record within indexed databases.
  • Strong citation metrics and measurable research visibility.
  • Contribution to pharmacological and biomedical advancement.
  • Demonstrated engagement in peer-reviewed scientific communication.

Conclusion

The academic profile of Jing-Ru Weng reflects substantial scholarly engagement within pharmacology and biomedical science. Publication productivity, citation impact, and research visibility collectively support recognition through the Best Researcher Award under the Global Academic Awards platform. The profile demonstrates sustained contribution to scientific advancement, scholarly communication, and translational biomedical investigation.[1]

References

    1. Elsevier. (n.d.). Scopus author details: Jing-Ru Weng, Author ID 7202292078. Scopus.https://www.scopus.com/authid/detail.uri?authorId=7202292078
    2. Journal of Medicinal Chemistry. (2007). Pharmacological investigations and therapeutic compound development.
    3. Molecular Cancer Therapeutics. (2009). Biomedical research impact and translational pharmacology.https://doi.org/10.1158/1535-7163.MCT-09-0168

Zhao Lichun | Pharmacology | Best Researcher Award

Published on by Global Academic Awards

Prof. Dr. Zhao Lichun | Pharmacology | Best Researcher Award

Prof. Dr. Zhao Lichun | Guiyang College of Traditional Chinese Medicine | China

Prof. Dr. Zhao Lichun, an esteemed scholar from Changchun, Jilin Province, China, has established himself as a leading researcher in the fields of trace elements and traditional Chinese medicine. With a Ph.D. and postdoctoral fellowship at Hong Kong Baptist University, he currently serves as a researcher, doctoral supervisor, and Director of the Research Department and Center for Trace Elements and Health Development at Guizhou University of Chinese Medicine. Additionally, he is the executive editor-in-chief of Trace Elements and Health Research, Director of Guizhou Laboratory, and Guangxi Key Laboratory for the Development of Endangered Medicinal Materials Resources. Widely recognized for his academic leadership, he has introduced pioneering concepts such as “elemental traditional Chinese medicine” and identified rubidium as a key trace element essential for human health. His prolific contributions include over two hundred publications, numerous patents, and national awards, positioning him as a trailblazer in scientific innovation and healthcare advancement.

Publication Profile

Scopus

Education

Prof. Zhao Lichun’s academic journey reflects a deep commitment to scientific research and medical innovation. He earned his doctoral degree in China, focusing on the intersection of trace elements and traditional Chinese medicine, and subsequently pursued a prestigious postdoctoral fellowship at Hong Kong Baptist University. His training allowed him to integrate modern scientific methods with traditional medicine, bridging ancient knowledge with contemporary biomedical research. Throughout his academic development, he consistently explored how trace elements influence human health, leading him to propose novel concepts such as “elemental traditional Chinese medicine.” His interdisciplinary education provided him with a strong foundation in chemistry, medicine, and health sciences, which has shaped his groundbreaking contributions to the study of essential trace elements like rubidium. By combining rigorous scientific inquiry with innovative theoretical frameworks, Prof. Zhao has become a recognized academic leader whose educational background underpins his extensive research achievements.

Experience

Prof. Zhao Lichun has accumulated extensive professional experience across research, teaching, leadership, and editorial roles. He serves as a doctoral supervisor and Director of the Research Department and Center for Trace Elements and Health Development at Guizhou University of Chinese Medicine. In addition, he leads the Guizhou Laboratory and the Guangxi Key Laboratory for the Development of Endangered Medicinal Materials Resources. As executive editor-in-chief of Trace Elements and Health Research, he plays a key role in advancing scholarly communication. His influence extends to national-level scientific initiatives, serving as a project evaluation expert for the China National Science and Technology Award, National Key R&D Program, and the National Natural Science Foundation. With leadership positions in professional associations related to health medicine, big data, artificial intelligence, diet research, and elderly healthcare, Prof. Zhao combines academic rigor with institutional guidance, contributing to both innovation and policy development.

Research Focus

Prof. Dr. Zhao Lichun’s research focus lies at the intersection of trace element science, traditional Chinese medicine, and modern biomedical innovation. His work emphasizes the critical roles of elements such as copper, iron, zinc, selenium, rubidium, silicon, chromium, and vanadium in human health, with particular attention to their involvement in neurodegenerative diseases like Alzheimer’s. He has pioneered the concept of “elemental traditional Chinese medicine,” exploring how minerals and trace elements can be harnessed for therapeutic benefits in chronic conditions, cancer, inflammatory diseases, and metabolic disorders. His studies highlight the mechanisms of action of compounds such as rosmarinic acid in cancer cell regulation, the protective effects of rubidium salts in ulcerative colitis, and the role of traditional medicine in enhancing recovery in chronic rhinosinusitis. Additionally, he explores nanomaterials and enzyme microreactors to improve therapeutic stability and efficiency. His multidisciplinary approach integrates pharmacology, molecular biology, and clinical applications to advance healthcare innovation.

Publication Top Notes

  • Bacteriostatic activity and mechanism of minerals containing rubidium
    Year: 2025

  • Traditional Chinese medicine in chronic rhinosinusitis: Mechanisms and postoperative recovery
    Year: 2025 | Citations: 3

  • Rosmarinic acid promotes mitochondrial fission and induces ferroptosis in triple-negative breast cancer cells
    Year: 2025 | Citations: 13

  • Interfacial Stabilization through MOF-Polymer Core-Shell Design: Ultraefficient, Stable and Recyclable Enzymatic Microreactors
    Year: 2025

  • Rubidium salt can effectively relieve the symptoms of DSS-induced ulcerative colitis
    Year: 2024 | Citations: 22

Conclusion

Prof. Zhao Lichun’s outstanding academic achievements, innovative research contributions, and leadership in advancing traditional Chinese medicine and trace element science make him a strong candidate for the Research for Best Researcher Award. With further international expansion of his research collaborations and recognition, he is well-positioned to become a truly global authority in his field.

Julio César Fernández Travieso | Clinical Pharmacology | Best Researcher Award

Published on by Global Academic Awards

Prof. Dr. Julio César Fernández Travieso | Clinical Pharmacology | Best Researcher Award

Prof. Dr. Julio César Fernández Travieso, National Centre for Scientific Research, Cuba

Prof. Dr. Julio César Fernández Travieso is a distinguished Cuban pharmaceutical scientist and Head of the Clinical Trials Unit at the National Centre for Scientific Research in Havana. He earned his BSc in Pharmaceutical Sciences in 1996 and completed his PhD in 2003. As a Senior Researcher and Full Academician of the Cuban Academy of Sciences, he has made significant contributions to the clinical development of natural-origin pharmaceuticals. With over 150 scientific publications and more than 120 conference presentations, his work has had a wide-reaching impact on experimental pharmacology and clinical research in Cuba.

Publication Profile

Scopus

Orcid

🎓 Education

Prof. Dr. Fernández Travieso completed his Bachelor of Science in Pharmaceutical Sciences from Havana University in 1996. He pursued advanced academic training and was awarded a PhD in Pharmaceutical Sciences in 2003. His education provided a comprehensive foundation in experimental pharmacology, pharmaceutical formulation, and clinical research methodologies. These qualifications enabled him to lead major clinical studies and serve in senior research roles. His academic background is firmly rooted in the development of therapeutics derived from natural sources, particularly those innovated in Cuba.

💼 Experience

Dr. Julio César Fernández Travieso currently serves as the Head of the Clinical Trials Unit at the National Centre for Scientific Research, Havana. With a career spanning over two decades, he has led multiple Phase I–IV clinical trials for novel therapeutics developed in Cuba. He is a Senior Investigator specializing in Clinical Pharmacology and has contributed to drug development, safety monitoring, and pharmacodynamic studies. His leadership has enabled the translation of research into approved therapeutic products. He also holds the title of Full Academician of the Cuban Academy of Sciences.

🏅 Awards and Honors

Prof. Dr. Fernández Travieso has received numerous national and international recognitions for his work in pharmaceutical sciences and clinical research. Several of his more than 120 scientific presentations have earned awards at global conferences. His appointment as a Full Academician of the Cuban Academy of Sciences highlights his standing in the scientific community. These honors reflect his role in advancing Cuba’s pharmaceutical innovation, particularly in clinical evaluation and development of natural products. His contributions have positioned him as a scientific leader in Latin America’s biomedical research landscape.

🔍 Research Focus

Dr. Fernández Travieso’s primary research interest lies in experimental pharmacology and conducting Phase I–IV clinical trials of natural-origin pharmaceuticals. He has played a pivotal role in evaluating and validating Cuban-developed products such as Policosanol, Abexol, Prevenox, Vasoactol, and Palmex. His work bridges laboratory pharmacology and clinical application, ensuring rigorous scientific evidence supports therapeutic claims. His research addresses chronic conditions like cardiovascular and metabolic disorders using innovative natural compounds. He also explores drug safety, efficacy, and pharmacokinetics in human populations.

Publication Top Notes

  • Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study 🧑‍⚕️, 2025

  • Comparative Study of the Efficacy and Safety of the Ozonated Sunflower Oil, Ketoconazole and Terbinafine in Patients with Dermatophytosis 💊, 2024

  • Beeswax Alcohol Prevents Low-Density Lipoprotein Oxidation and Demonstrates Antioxidant Activities in Zebrafish Embryos and Human Subjects: A Clinical Study 🧬, Cited by: 6, 2024

  • Effects of Policosanol in Patients with Metabolic Syndrome: A Six-Month Study 💉, Cited by: 6, 2020

  • Efficacy and Tolerability of Roystonea Regia Lipid Extract (D-004) and Terazosin in Men with Symptomatic Benign Prostatic Hyperplasia: A 6-Month Study 🔬, Cited by: 7, 2019

  • Concomitant Use of Policosanol and Antiplatelet Drugs in Older Patients 💊, 2019

  • Non-Cardioembolic Ischemic Stroke Hypertensive Patients, A Therapeutic Hope. Reply 🧠, 2019

 

Fatma Moharram | Biological Activity | Best Researcher Award

Published on by Global Academic Awards

Prof. Fatma Moharram | Biological Activity | Best Researcher Award

Prof. Fatma Moharram at Helwan University, Egypt

Fatma Abdel Kader Mohamed Moharram is a distinguished professor and researcher in Pharmacognosy with extensive academic and research experience. She has held prominent positions at esteemed institutions, including Helwan University, King Faisal University, and Taibahu University. Her expertise spans natural products chemistry, medical education, and biological evaluation of plant extracts. As a department head and vice dean, she has played a pivotal role in academic leadership. With numerous publications, editorial memberships, and conference participations, she has significantly contributed to pharmaceutical sciences, mentoring many postgraduate students and advancing research in pharmacognosy and phytochemistry.

Publication Profile

Orcid

Educational Background🎓

Fatma Moharram holds a Ph.D. in Pharmaceutical Sciences (Pharmacognosy) from Cairo University (1996), focusing on the phytochemical and biological study of Cordia species. She earned an M.Sc. in Pharmaceutical Sciences from Cairo University (1992) with research on Melaleuca species and a B.Pharm.Sc. from the same institution. Additionally, she completed an M.Sc. in Medical Education through a distance learning program between Suez Canal and Maastricht Universities. Her multidisciplinary education has provided her with a strong foundation in pharmacognosy, natural product chemistry, and medical education, shaping her extensive research and teaching career across multiple institutions worldwide.

Professional background👩‍🏫

With over three decades in academia, Fatma Moharram has served as a professor, researcher, and administrator. She worked at the National Research Centre (Egypt), Helwan University, King Faisal University, and Taibahu University. She led departments, supervised numerous postgraduate theses, and played key roles in medical education. As Vice Dean for Community Service and Environment Development (2017-2021), she spearheaded initiatives enhancing educational effectiveness. Her international experience includes a postdoctoral fellowship at Humboldt University and editorial roles in global pharmaceutical journals. She has contributed significantly to pharmacognosy education, research projects, and curriculum development across multiple universities.

Awards and Honors🏆

Fatma Moharram has received numerous accolades for her contributions to pharmacognosy and medical education. She has been recognized for her impactful research, leadership in academic development, and participation in international scientific conferences. As a reviewer for prestigious journals and promotion committees, she has influenced pharmaceutical research globally. She has also played a pivotal role in research projects funded through international collaborations. Her leadership in organizing and chairing conferences at Helwan University, Al-Azhar University, and beyond has cemented her reputation as a key figure in pharmacognosy and natural product sciences.

Research Focus🔬

Fatma Moharram specializes in pharmacognosy and the chemistry of natural products, particularly the isolation and identification of bioactive compounds from plants and endophytes. Her research explores essential oils, polyphenols, and flavonoids, with applications in pharmaceuticals and medicine. She has led studies on biological evaluations of plant extracts for antimicrobial, antioxidant, and anti-inflammatory properties. Her expertise extends to chromatography, spectroscopy, and biosynthesis, contributing to drug discovery. As a reviewer and editor for international journals, she continuously advances research in phytochemistry, ethnopharmacology, and medicinal plant sciences, bridging traditional medicine with modern pharmaceutical applications.

Publication Top Notes

1️⃣ Comprehensive Assessment of the Antidiarrheal Properties of Polyphenols from Psidium cattleianum Sabine’s Aerial Parts 📖
Year: 2025 | Journal: Journal of Ethnopharmacology

2️⃣ Bioactive Metabolites Identified from Aspergillus terreus Derived from Soil 🦠
Year: 2023 | Journal: AMB Express

3️⃣ Melaleuca rugulosa (Link) Craven Tannins: Appraisal of Anti-inflammatory, Radical Scavenging Activities, and Molecular Modeling Studies 🌿
Year: 2022 | Journal: Journal of Ethnopharmacology

Conclusion

Fatma Abdel Kader Mohamed Moharram is a distinguished researcher and academic with extensive expertise in Pharmacognosy, natural product chemistry, and medical education. Holding a Ph.D. in Pharmaceutical Science and multiple academic positions at prestigious institutions like Helwan University, King Faisal University, and Taibahu University, she has made significant contributions to research and education. Her work includes isolating and identifying bioactive compounds, analyzing essential oils, and evaluating plant extracts’ biological properties. With numerous publications, active participation in international conferences, leadership roles, editorial contributions to renowned journals, and supervision of MSc and Ph.D. theses, she has demonstrated exceptional academic influence and research impact. As a reviewer for various research projects and promotions, she upholds high research standards, making her a highly deserving candidate for the Best Researcher Award.

 

 

Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award

Published on by Global Academic Awards

Assoc. Prof. Dr. Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award

Assoc. Prof. Dr. Ismael Lares-Asseff, Instituto Politécnico Nacional, CIIDIR Durango, Mexico

Dr. Ismael Lares-Asseff, a prominent Mexican researcher, holds a degree in Medicine from UJED and a specialty in Pediatrics from IMAN and UNAM. He earned his Master’s and Ph.D. in Medical Sciences from UNAM, receiving the prestigious “Gabino Barreda Medal.” Mentored by renowned researcher Dr. Joaquín Cravioto, Dr. Lares founded Latin America’s first Clinical Pharmacokinetics Laboratory in 1982. His work spans pediatric pharmacokinetics, malnutrition, and pharmacogenetics among diverse ethnic groups, and he authored influential books like Clinical Pharmacology in Pediatrics and Pharmacogenomics in Latin America. With 190 publications, 671 citations, and numerous awards, he is a leader in personalized medicine.

 

Publication Profile

Scopus

Orcid

Background and Academic Achievements

Assoc. Prof. Dr. Ismael Lares-Asseff holds a distinguished background in medicine, earning degrees and accolades throughout his extensive career. With an MD from the Universidad Juárez del Estado de Durango (UJED), he specialized in Pediatrics through the Children’s Hospital of IMAN and the National Autonomous University of Mexico (UNAM). His academic journey culminated in a Master’s and Doctorate in Medical Sciences from UNAM, where he was awarded the “Gabino Barreda Medal” for his outstanding academic achievements.

Contributions to Pediatric Research and Clinical Pharmacokinetics

Under the mentorship of Dr. Joaquín Cravitoto, a globally respected figure in pediatric research, Dr. Lares-Asseff developed Mexico’s first Clinical Pharmacokinetics Laboratory in 1982. His early research primarily focused on understanding the impact of malnutrition on pediatric pharmacokinetics, producing findings published in prestigious journals. These works led to his internationally recognized book, Clinical Pharmacology in Pediatrics: Pharmacokinetics and Pharmacogenomics, awarded by the Mexican Academy of Pediatrics.

Conclusion

Assoc. Prof. Dr. Ismael Lares-Asseff is an ideal candidate for the Research for Lifetime Achievement Award. His contributions to pediatric pharmacology, pharmacogenetics, and personalized medicine embody a lifelong commitment to advancing medical science and patient care.

 

Publication Top Notes

  • 🧬 Influence of Age, Gender, and BMI on IV Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery, Rivera-Espinosa, L., Vicencio-Rosas, E., et al., Dose-Response, 2024, 0 citations.
  • 👨‍⚕️ Population Pharmacokinetics and Pharmacodynamics of L-asparaginase and Its Impact on Pancreatitis in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Drug and Chemical Toxicology, 2024, 0 citations.
  • 💉 Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Nutrition and Cancer, 2024, 0 citations.
  • 🧪 Impact of SNPs and Nutrition on Doxorubicin Pharmacokinetics and Cardiotoxicity in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Journal of Oncology Pharmacy Practice, 2023, 3 citations.
  • 🌎 Barriers to Pharmacogenomics in Latin America and the Caribbean: Drug/Gene Pairs, Salas-Hernández, A., Galleguillos, M., et al., Frontiers in Pharmacology, 2023, 9 citations.
  • 📝 Pharmacogenetics and Pharmacogenomics in Latin America: Perspectives, López-Cortés, A., Esperón, P., Lares-Asseff, I., et al., Frontiers in Pharmacology, 2023, 3 citations.
  • 🐾 Silver Nanoparticles in Treating Distemper in Dogs: A Clinical Trial, Gastelum-Leyva, F., Pena-Jasso, A., et al., Viruses, 2022, 2 citations.
  • 🔬 Mitochondrial Dysfunction Caused by Zinc Oxide Nanoparticles, Patrón-Romero, L., et al., Crystals, 2022, 16 citations.
  • 🧬 Effect of Levetiracetam on Placental Transporter Gene Expression in Mice, Blanco-Castañeda, R., et al., Epilepsia, 2022, 0 citations.
  • ❤️ Genetic Polymorphisms and Doxorubicin Cardiotoxicity in Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Pharmacogenetics and Genomics, 2021, 8 citations.